RNS Number : 0994L
Fusion Antibodies PLC
11 December 2025

REACH - Non-regulatory announcement*

11 December 2025

Fusion Antibodies plc
("Fusion" or the **"Company")**

Mammalian Display video

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that ahead of the commercial launch of the OptiMAL® Human Antibody Discovery platform at the Antibody Engineering and Technology conference in San Diego on 15 December 2025, Fusion has prepared a short video of Dr Richard Buick, CSO, explaining some of the features, science and technology behind the Company's Mammalian Display technology. The technology has been combined with Fusion's Opti-library to create the OptiMAL® library. OptiMAL® is intended to be used to discover novel human antibodies against any target. The mammalian display platform library design and method is protected by US patent US12378696. The Mammalian Display technology can also be used with other antibody libraries.

The video can be viewed on the Investor Hub section of Fusion's website at, https://investorhub.fusionantibodies.com/s/7ea305.

Other Mammalian Display technologies are available and have been summarised in the scientific literature e.g. Slavny P, Hegde M, Doerner A, Parthiban K, McCafferty J, Zielonka S and Hoet R (2024) Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects. Front. Immunol. 15:1469329. doi: 10.3389/fimmu.2024.1469329.

Fusion Antibodies has compared its own Mammalian Display technology to the competitor platforms in the review article and identified several superior advantages. The most significant are its transduction efficiency of over 70% and its ability to support very large libraries, exceeding 10^9 variants. These are summarised in the table below:

Technology	**OptiMAL®**	**Retrocyte Display**	**Other Lentiviral mammalian display**	**Transposase-mediated integration**	**Nuclease-directed integration**	**Recombinase-mediated integration**
Integration Efficiency	**>70%**	<5%	0.5-5%	6-7.5%	0.5-5%	1.7%
Reported library sizes	**>10^9**	10^6-10^8	10^6	10^6	10^6-10^8	10^6-10^8

If shareholders or prospective investors have further queries regarding the Mammalian Display platform, please submit questions you may have regarding this update using the facility provided.

Investor Presentation and Q&A: OptiMAL® Launch

Adrian Kinkaid, CEO of Fusion will provide a pre-recorded presentation and Q&A session on the OptiMAL® launch from the Antibody Engineering & Therapeutics Conference via the Company's Investor Hub on Tuesday, 16 December 2025, at 16:00 GMT.

The presentation is open to all existing and potential shareholders. Questions are encouraged and can be pre-submitted via the webinar page.

Register and submit your questions here: https://investorhub.fusionantibodies.com/webinars/mPqXOr-optimal-r-launch-investor-q-a

No material new information will be included in the presentation or Q&A.

Fusion Antibodies wants to keep its investors up to date with developments in the Company technology and offerings. We have therefore created a space on the Investor Hub which in contains an increasing number of videos providing more information which may be of interest to investors. This can be found here, https://investorhub.fusionantibodies.com/s/1b6535.

Enquiries:

Investor questions on this announcement

We encourage all investors to share questions on this announcement via our investor hub — Investor hub

Fusion Antibodies plc — www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer — Via Walbrook PR
Stephen Smyth, Chief Financial Officer

Allenby Capital Limited — Tel: +44 (0) 20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

Shard Capital Partners LLP

Damon Heath (Joint Broker) — Tel: +44 (0) 207 186 9952

Walbrook PR — Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy — Mob: +44 (0)7876 741 001

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx ^{TM} platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

***About Reach announcements**

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRATMBBTMTJBTAA